Adjuvant chemotherapy in T1a/bN0 breast cancer with a high 21-gene recurrence score (> 25): a 10-year follow-up in a real-world cohort
In this study cohort, patients with T1a/bN0 BC, RS > 25 that received aCT, did not have improved outcomes and the 21-Gene RS > 25 was not found to be predictive, possibly due to the low number of events observed.
Authors
- Daniel A. Goldstein (ORCID: https://orcid.org/0000-0002-8082-9622)
- Ariel Hammerman
- Hadar Goldvaser (ORCID: https://orcid.org/0000-0002-9557-4634)
- Ilan Feldhamer
- Daniela Katz (ORCID: https://orcid.org/0000-0002-4021-7883)
- Yael Wolff-Sagy
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Tel Aviv University (IL)
- Rabin Medical Center (IL)
- Shaare Zedek Medical Center (IL)
- Clalit Health Services (IL)
Publication Details
- Journal
- Breast Cancer
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1007/s12282-024-01652-9
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Hebrew University of Jerusalem